Alzheimer's 'breakthrough' stalls: why a much-hyped drug is

The benefits of drugs such as donanemab, aducanumab and lecanemab are proving harder to quantify than potential harms, experts say

Related Keywords

United Kingdom , Netherlands , Cambridge , Cambridgeshire , Paris , France General , France , Australia , Australian , Eli Lilly , Anne White , Ian Scott , Timothy Daly , Sebastian Walsh , Radboud University Medical Centre , Al Jazeera , Sorbonne University , Therapeutic Goods Administration , University Of Cambridge , Alzheimer Research United Kingdom , Drug Administration , Research United Kingdom , Edo Richard , Princess Alexandra , Prof Ian Scott ,